Sutro biopharma

Key events shows relevant news articles on days with large price movements.

Sutro Biopharma, Inc. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in STRO is an ADC targeting folate receptor alpha , a cell-surface protein highly expressed in gynecological cancers. As of [update] Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine -based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal. In July , Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders.

Sutro biopharma

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. Many thanks to our Sutro team for their continuous efforts in placing our patients first. We appreciate and value all the work you have done! To read the report, click the link. Dedicated to our Patients and Changing the Future of Oncology. Learn More. Sutro Biopharma, Inc. Our Technology. Our innovative Research and development has resulted in six product candidates Our Pipeline Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. News Releases. Leadership Team.

Net profit margin.

Skip to main content. Sutro Biopharma, Inc. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. Vaxcyte, Inc.

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. Many thanks to our Sutro team for their continuous efforts in placing our patients first. We appreciate and value all the work you have done! To read the report, click the link. Dedicated to our Patients and Changing the Future of Oncology.

Sutro biopharma

Sutro Biopharma, Inc. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in STRO is an ADC targeting folate receptor alpha , a cell-surface protein highly expressed in gynecological cancers. As of [update] Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine -based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal. In July , Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. In , Sutro and Celgene announced they had refocused their immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen BCMA. Sutro was named one of Fierce Biotech's Fierce 15 in Contents move to sidebar hide.

Billar caesars

Sign Up for Email Alerts. Net cash used or generated for core business activities. Operating expense Represents the total incurred expenses through normal operations. Homeless Prenatal Program. Learn More. Net profit margin. Trevi Therapeutics Inc. To read the report, click the link. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Sum of the combined debts a company owes. PMID Net change in cash.

.

ALLK 7. Vaxcyte Inc. Net change in cash. Please consult your broker or financial representative to verify pricing before executing any trades. Biotechnology company based in South San Francisco, California. Dividend yield. The amount by which a company's cash balance increases or decreases in an accounting period. Unsourced material may be challenged and removed. You may be interested in info This list is generated from recent searches, followed securities, and other activity. Net profit margin Measures how much net income or profit is generated as a percentage of revenue.